featured
SWOG S1801: Pathologic Response With Neoadjuvant vs Adjuvant Pembrolizumab in Resectable Stage IIIb–IV Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: